|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBSCO_on1231611112 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
210116s2020 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d N$T
|d OCLCF
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 1774078929
|
| 020 |
|
|
|a 9781774078921
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)1231611112
|
| 050 |
|
4 |
|a RM275
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Sripathi, Shiv Sanjeevi.
|
| 245 |
1 |
0 |
|a Immunotherapy
|
| 260 |
|
|
|a Ashland :
|b Delve Publishing,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (283 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Cover -- Copyright -- DECLARATION -- ABOUT THE EDITORS -- TABLE OF CONTENTS -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 History of Immunotherapy -- 1.1 Introduction -- 1.2 Immune System -- 1.3 Therapies based on Anti-bodies -- 1.4 Immunosuppression and reduction in treatment -- 1.5 Cancer Vaccines -- 1.6 Using viruses to heal -- 1.7 Final points -- 1.8 References -- Chapter 2 Immunotherapy: Looking at the Details -- 2.1 The basics -- 2.2 Overview of Immunotherapy -- 2.3 Antibodies and Tumor-specific monoclonal antibodies (mAbs) -- 2.4 Cytokines for Treatment
|
| 505 |
8 |
|
|a 2.5 Oncolytic Viruses -- 2.6 Dendritic Cells and Immunotherapy -- 2.7 PRR Agonists -- 2.8 Immune Checkpoint Inhibitors: -- 2.9 Vaccines -- 2.10 Adoptive Cell Transfer (ACT) Strategies -- 2.11 Other Approaches -- 2.12 Summary -- 2.13 References -- Chapter 3 Summarizing The Challenges and Solutions -- 3.1 Looking at Consistenc -- 3.2 Identification of Clinically Significant Biomarkers -- the Inherent Difficulties -- 3.3 Requirement for an Increased Number of Predictive Biomarkers -- 3.4 Efficacy being Impeded by Tumor Heterogeneity -- 3.5 Resistance to Drug Treatment -- Development
|
| 505 |
8 |
|
|a 3.6 Efficacy Evaluation Needs Distinct Clinical Study Designs -- 3.7 Cancer Immunotherapy Drugs -- An Expensive Proposition -- 3.8 The Challenges and Solutions -- 3.9 The way Ahead -- 3.10 References -- Chapter 4 Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells -- Abstract -- Introduction -- Materials and Methods -- Results -- Discussion -- References -- Chapter 5 A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer -- Abstract -- Introduction -- Results -- Discussion -- Conclusion -- Methods -- References
|
| 505 |
8 |
|
|a Chapter 6 Immunotherapy In Gastrointestinal Cancers -- Abstract -- Gastrointestinal Cancers: Where Do We Stand? -- The Rationale For Immunotherapy In Gi Cancers -- Immunotherapeutic Strategies: A General Overview -- Focus On Gastric, Esophageal, and Pancreatic Cancers -- Focus on Colorectal Cancer -- Focus on Hepatocellular Carcinoma -- Possible Biomarkers For Immunotherapy: The Pathologist Perspective -- Back To The Bench: Biomarkers And Genetic Signatures as Predictive Factors -- Future Perspectives -- References -- Chapter 7 Harnessing the Microbiome to Enhance Cancer Immunotherapy -- Abstract
|
| 505 |
8 |
|
|a Introduction -- Coley's Toxin In Tumor Immunotherapy -- Commensal Microflora Regulates The Innate and Adaptive Immune System -- Toll-Like Receptors in Cancer Immunotherapy -- Tlr Expression on T Cells and Cancer Cells -- Vaccines Promote Weak T Cell-Mediated Tumor Regression -- Act Therapy: A Promising Cancer Treatment -- Lymphodepletion Augments Act Therapy -- Mechanisms Of Tbi Effectiveness: Sinks, Suppressors, and Microbial Activators -- Lymphodepletion Activates The Innate Immune System -- Mimicking Tbi: Promoting The Benefits While Removing The Harm
|
| 500 |
|
|
|a Potentiating Antitumor T Cells: Costimulation, Cytokines, and Microbial Signals.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Immunotherapy.
|
| 650 |
|
2 |
|a Immunotherapy
|
| 650 |
|
6 |
|a Immunothérapie.
|
| 650 |
|
7 |
|a Immunotherapy
|2 fast
|
| 700 |
1 |
|
|a Subramaniam, Raghu.
|
| 776 |
0 |
8 |
|i Print version:
|a Sripathi, Shiv Sanjeevi.
|t Immunotherapy: a review and update.
|d Ashland : Delve Publishing, ©2020
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2725296
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL6453536
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 2725296
|
| 994 |
|
|
|a 92
|b IZTAP
|
